Kura Oncology to Present at Bank of America Merrill Lynch Health Care Conference
May 08, 2019 08:00 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 08, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones
May 07, 2019 16:05 ET
|
Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track – – Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentations at EHA...
Kura Oncology to Report First Quarter 2019 Financial Results
April 30, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications
April 02, 2019 16:04 ET
|
Kura Oncology, Inc.
– Tipifarnib is a farnesyl transferase inhibitor that downregulates CXCL12 – – Gene expression of the exclusively farnesylated RHOE and PRICKLE2 proteins associated with CXCL12 expression – –...